Patent · US Active

Pharmaceutical compounds

US11377443B2 · kind B2 · utility

0Cited by
3References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 14, 2020
Grant dateJul 5, 2022
Priority date
Expiry dateJun 19, 2040

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K45/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.